S.C Centrul de Gastroenterologie Dr. Goldis S.R.L
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldis, Adrian
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Completed
3
200
US
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
07/24
09/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
Hp-EuReg, NCT02328131: European Registry on the Management of Helicobacter Pylori Infection

Recruiting
N/A
10000
Europe, RoW
Javier P. Gisbert
H. Pylori Infection
12/34
12/34
CROCO, NCT05420233: The Study: CROhn's Disease COhort Study

Recruiting
N/A
600
Europe, RoW
MRE, Magnetic Resonance Enterography
GLSMED Learning Health S.A., AbbVie
Crohn Disease
08/28
08/28

Download Options